Replies to post #1571 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Teva will never be allowed to buy MNTA for the reasons you stated so this topic is moot. Regardless, the assumption that nobody would want own branded Copaxone if MNTA/TEVA brought generic Copaxone to market ascribes no value to branded Copaxone under this scenario.

If Teva and MNTA were joining forces to bring a generic Copaxone to market, success would be virtually guaranteed. Under this scenario, why would a third party want to promote branded Copaxone knowing that a substantial portion of the benefit would accrue to a generic competitor?

They wouldn’t, of course, and hence branded Copaxone under such a scenario would effectively become just another generic.

This whole discussion is moot for the reasons already mentioned.